APS6-45|2188236-41-9|-陌孚医药/Medlife

您当前的位置：

APS6-45

目录号: PL10837 纯度: ≥99%

CAS No. :2188236-41-9

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	APS6-45
中文别名	化合物APS6-45
英文名称	APS6-45
英文别名	4-(4-(3-(2-fluoro-5-(perfluoropropan-2-yl)phenyl)ureido)phenoxy)-N-methylpicolinamide;FC1=C(C=C(C=C1)C(C(F)(F)F)(C(F)(F)F)F)NC(NC1=CC=C(OC2=CC(=NC=C2)C(=O)NC)C=C1)=O;APS6-45;4-[4-[[2-fluoro-5-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;CID 131953288;2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-;APS6-45,calibrated,signaling,TCI,Inhibitor,APS-6-45,APS645,Carcinoma,Thyroid,Ras,antitumor,Medullary,MAPK,APS6 45,tumor,inhibit
Cas No.	2188236-41-9
分子式	C₂₃H₁₆F₈N₄O₃
分子量	548.39
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	APS6-45 是一种口服活性的肿瘤校准抑制剂 (TCI)。APS6-45 抑制 RAS/MAPK 信号传导并表现出抗肿瘤活性。
生物活性	APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.
性状	Solid
体外研究(In Vitro)	APS6-45 (3-30 nM; 3 weeks) strongly suppresses TT human Medullary Thyroid Carcinoma (MTC) cells colony formation in a soft agar assay. APS6-45 (1 μM; 1 h) strongly inhibits RAS pathway activity signaling in human MTC cell lines TT and MZ-CRC-1. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	APS6-45 (10 mg/kg; p.o. daily for 30 d) inhibits growth of TT tumors in mice and does not affect body weight. APS6-45 (0.1-160 mg/kg; a single p.o.) does not cause detectable toxic effects in mice. APS6-45 (20 mg/kg; a single p.o.) exhibits long half-life (5.6 h), C max (9.7 μM) and AUC 0-24 (123.7 μM?h) in mice. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Sonoshita M, et, al. A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol. 2018 Mar;14(3):291-298.

溶解度数据	In Vitro: DMSO : 250 mg/mL (455.88 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品